EC OKs expanded use for Roche's cancer med Perjeta; shares up 2%

|About: Roche Holding Ltd ADR (RHHBY)|By:, SA News Editor

The European Commission approves Roche's (OTCQX:RHHBY +1.9%) Perjeta (pertuzumab), in combination with Herceptin (trastuzumab) and chemo, for post-surgery treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.

The data supporting the approval was generated in the Phase 3 APHINITY study that showed treatment with Perjeta significantly reduced the risk of invasive breast cancer recurrence or death compared to Herceptin and chemo alone.

Perjeta was previously approved to treat advanced (metastatic) HER2-positive breast cancer.

Subscribe for full text news in your inbox